½ÃÀ庸°í¼­
»óǰÄÚµå
1790251

ºÐÀÚ¼¼Æ÷ À¯ÀüÇÐ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ¿ëµµº°, ±â¼úº°, Á¦Ç°º°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2033³â)

Molecular Cytogenetics Market Size, Share & Trends Analysis Report By Application, By Technology, By Product, By End Use, By Region, And Segment Forecasts, 2025 - 2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 136 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ºÐÀÚ¼¼Æ÷ À¯ÀüÇÐ ½ÃÀå °³¿ä

¼¼°è ºÐÀÚ¼¼Æ÷ À¯ÀüÇÐ ½ÃÀå ±Ô¸ð´Â 2024³â 24¾ï ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2025-2033³â 11.7%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÏ¿© 2033³â¿¡´Â 63¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÓ»ó Áø´Ü ¹× ¿¬±¸, ƯÈ÷ Á¾¾çÇÐ, À¯Àü¼º Áúȯ, »êÀü °Ë»ç¿¡¼­ ºÐÀÚ¼¼Æ÷À¯ÀüÇÐ ±â¹ýÀÇ È°¿ëÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ½ÃÀå È®´ë¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ µµ±¸´Â ¿°»öü ÀÌ»ó¿¡ ´ëÇÑ °íÇØ»óµµ ºÐ¼®À» Á¦°øÇϸç, ÃֽŠ°Ë»ç½Ç ¹× ÀÓ»ó ¿öÅ©Ç÷ο쿡 ÇʼöÀûÀÔ´Ï´Ù. Çü±¤ in situ hybridization(FISH), ºñ±³ À¯Àüü ÇÏÀ̺긮µåÈ­(CGH), ¾î·¹ÀÌ ±â¹Ý ±â¹ýÀÇ Àû¿ëÀÌ È®´ëµÇ°í ÀÖ´Â °Íµµ ºÐÀÚ¼¼Æ÷À¯ÀüÇÐÀÇ Ã¤Åà Ȯ´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ »ç¿ë È®´ë, ÀÚµ¿È­ ¹× ¿µ»óÈ­ ±â¼ú Çâ»óÀ¸·Î º´¿ø, Çмú ±â°ü, ¿¬±¸¼¾ÅÍ ½ÃÀå ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

À¯Àüü µ¥ÀÌÅÍÀÇ ¾çÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¸ÖƼ¿À¹Í½º Á¢±Ù¹ýÀÇ ÅëÇÕ°ú »ý¹°Á¤º¸ÇÐ µµ±¸ÀÇ ¹ßÀüÀ¸·Î ºÐÀÚ¼¼Æ÷À¯ÀüÇÐ ºÐ¾ß°¡ Å©°Ô °­È­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â´É °­È­´Â ´ë±Ô¸ð À¯Àüü µ¥ÀÌÅÍ ¼¼Æ®ÀÇ °ü¸®, ºÐ¼® ¹× ÇØ¼®À» ¿ëÀÌÇÏ°Ô Çϰí, ¿°»öü º¯È­¿Í Áúº´°úÀÇ À¯ÀǹÌÇÑ ¿¬°ü¼ºÀ» ½±°Ô ¹ß°ßÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ±× °á°ú, ºÐÀÚ¼¼Æ÷ À¯ÀüÇп¡ ´ëÇÑ ¼ö¿ä°¡ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¬±¸½ÇÀº ¿¬±¸¿Í Áø´Ü ¸ðµÎ¿¡¼­ ÀÌ·¯ÇÑ µµ±¸¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù.

2023³â 12¿ù, ·çÇÉ´ÙÀֱ̾׳뽺ƽ½º´Â Ÿ¹Ð³ªµÎ ÁÖ Ã¾³ªÀÌ¿¡ ÃÖ½Å½Ä Áö¿ª ·¹ÆÛ·±½º ¿¬±¸¼Ò¸¦ °³¼³Çß½À´Ï´Ù. ÀÌ ¿¬±¸¼Ò¿¡¼­´Â À¯¼¼Æ÷ºÐ¼®, ¼¼Æ÷Áø´Ü µî°ú ÇÔ²² ºÐÀÚÁø´ÜÇÐ, ƯÈ÷ ¼¼Æ÷À¯ÀüÇÐ µî ´Ù¾çÇÑ ¼­ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù. À̹ø È®ÀåÀ¸·Î °íǰÁú ºÐÀÚ¼¼Æ÷À¯ÀüÇÐ °Ë»ç¿¡ ´ëÇÑ Áö¿ª ³» Á¢±Ù¼ºÀÌ °­È­µÇ°í, Àεµ ³²ºÎ Áö¿ªÀÇ Áø´Ü ´É·Â Çâ»ó¿¡ µµ¿òÀÌ µÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ÀÌ·¯ÇÑ ÁÖ¿ä Áø´Ü¾÷üµéÀÇ ÅõÀÚ´Â ÀÏ»óÀûÀÎ ÀÓ»ó¿¡¼­ ¼¼Æ÷À¯ÀüÇÐÀÇ Á߿伺À» ÀÔÁõÇϰí, ÀÌ ±â¼úÀÇ À¯¿ë¼º°ú ÇâÈÄ ¼ºÀå °¡´É¼º¿¡ ´ëÇÑ ½ÃÀåÀÇ ½Å·Ú°¡ ³ô¾ÆÁ³À½À» ¹Ý¿µÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ºÐÀÚ¼¼Æ÷ À¯ÀüÇÐ ½ÃÀå : Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ºÐÀÚ¼¼Æ÷ À¯ÀüÇÐ ½ÃÀå : ÁÖ¿ä ¿ä¾à

  • ½ÃÀå Àü¸Á
  • ¿ëµµ ¹× ±â¼ú ÇöȲ
  • Á¦Ç° ¹× ÃÖÁ¾ ¿ëµµ ÇöȲ
  • °æÀï ±¸µµ ÇöȲ

Á¦3Àå ºÐÀÚ¼¼Æ÷ À¯ÀüÇÐ ½ÃÀå : ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
  • ½ÃÀå ¿ªÇÐ
  • »ê¾÷ ºÐ¼® Åø

Á¦4Àå ºÐÀÚ¼¼Æ÷ À¯ÀüÇÐ ½ÃÀå : ¿ëµµ ºñÁî´Ï½º ºÐ¼®

  • ºÐÀÚ¼¼Æ÷ À¯ÀüÇÐ ½ÃÀå : ¿ëµµ º¯µ¿ ºÐ¼®
  • À¯Àü¼º Áúȯ
  • Á¾¾çÇÐ
  • ¸ÂÃãÇü ÀÇ·á
  • ±âŸ

Á¦5Àå ºÐÀÚ¼¼Æ÷ À¯ÀüÇÐ ½ÃÀå : ±â¼ú ºñÁî´Ï½º ºÐ¼®

  • ºÐÀÚ¼¼Æ÷ À¯ÀüÇÐ ½ÃÀå : ±â¼ú º¯µ¿ ºÐ¼®
  • ºñ±³ À¯ÀüüÇÏÀ̺긮´ÙÀÌÁ¦À̼Ç
  • FISH
  • ¸é¿ªÁ¶Á÷È­ÇÐ
  • ÇÙÇü ºÐ¼®
  • ±âŸ

Á¦6Àå ºÐÀÚ¼¼Æ÷ À¯ÀüÇÐ ½ÃÀå : Á¦Ç° ºñÁî´Ï½º ºÐ¼®

  • ºÐÀÚ¼¼Æ÷ À¯ÀüÇÐ ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®
  • ±â±â
  • ¼Ò¸ðǰ
  • ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º

Á¦7Àå ºÐÀÚ¼¼Æ÷ À¯ÀüÇÐ ½ÃÀå : ÃÖÁ¾ ¿ëµµ ºñÁî´Ï½º ºÐ¼®

  • ºÐÀÚ¼¼Æ÷ À¯ÀüÇÐ ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
  • ÀÓ»ó½ÇÇè½Ç
  • º´¿ø ¹× º´¸® °Ë»ç½Ç
  • Çмú¿¬±¸±â°ü
  • Á¦¾à ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • ±âŸ

Á¦7Àå ºÐÀÚ¼¼Æ÷ À¯ÀüÇÐ ½ÃÀå : Áö¿ª ºñÁî´Ï½º ºÐ¼®

  • Áö¿ª ½ÃÀå ½º³À¼ô
  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦8Àå ºÐÀÚ¼¼Æ÷ À¯ÀüÇÐ ½ÃÀå : °æÀï ±¸µµ

  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â
  • ±â¾÷ °³¿ä
LSH 25.08.25

Molecular Cytogenetics Market Summary

The global molecular cytogenetics market size was estimated at USD 2.40 billion in 2024 and is projected to reach USD 6.39 billion by 2033, growing at a CAGR of 11.7% from 2025 to 2033. The market expansion is supported by the increasing use of molecular cytogenetic techniques in clinical diagnostics and research, particularly in oncology, genetic disorders, and prenatal testing.

These tools offer high-resolution analysis of chromosomal abnormalities, making them essential in modern laboratory and clinical workflows. The growing application of fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and array-based methods contributes to the rising adoption of molecular cytogenetics. Expanding use in personalized medicine and technological improvements in automation and imaging continue to strengthen market demand across hospitals, academic institutions, and research centers.

With the growing volume of genomic data, integrating multi-omics approaches and advancements in bioinformatics tools significantly enhances the molecular cytogenetics field. These enhancements facilitate better management, analysis, and interpretation of large genomic datasets, making it easier to discover meaningful links between chromosomal alterations and diseases. As a result, demand for molecular cytogenetics is expected to grow, with laboratories increasingly relying on these tools for both research and diagnostic applications.

In December 2023, Lupin Diagnostics unveiled a new state-of-the-art Regional Reference Laboratory in Chennai, Tamil Nadu. This laboratory offers a wide range of services, including molecular diagnostics and especially cytogenetics, alongside flow cytometry, cytology, and more. This expansion enhances regional access to high-quality molecular cytogenetic testing and supports better diagnostic capabilities in southern India. Such investments by major diagnostic providers validate cytogenetics' significance in routine clinical practice and reflect growing market confidence in the technology's utility and future growth potential.

Global Molecular Cytogenetics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global molecular cytogenetics market based on application, technology, product, end use, and region:

  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Genetic Disorders
  • Oncology
  • Personalized Medicine
  • Other Applications
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Comparative Genomic Hybridization
    • aCGH
    • sCGH
  • FISH
  • Immunohistochemistry
  • Karyotyping
    • Spectral
    • Virtual
  • Others
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Instruments
  • Consumables
  • Software & Services
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical & Research Laboratories
  • Hospitals & Path Labs
  • Academic Research Institutes
  • Pharmaceutical & Biotech Companies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1 Molecular Cytogenetics Market: Research Methodology And Scope

  • 1.1 Market Segmentation And Scope
    • 1.1.1 Segment Definitions
      • 1.1.1.1 Application Segment
      • 1.1.1.2 Technology Segment
      • 1.1.1.3 Product Segment
      • 1.1.1.4 End Use Segment
  • 1.2 Regional Scope
  • 1.3 Estimates And Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 Gvr's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information Or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List Of Secondary Sources
  • 1.11 List Of Abbreviations

Chapter 2 Molecular Cytogenetics Market: Executive Summary

  • 2.1 Market Outlook
  • 2.2 Application And Technology Snapshot
  • 2.3 Product And End Use Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 Molecular Cytogenetics Market: Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Related/Ancillary Market Outlook
  • 3.2 Market Dynamics
    • 3.2.1 Market Drivers Analysis
      • 3.2.1.1 Rapid Technological Advancements
      • 3.2.1.2 Increasing Prevalence Of Genetic Disorders
      • 3.2.1.3 Growing Application In Oncology
      • 3.2.1.4 Increasing Demand For Personalized Medicine
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 High Costs Of Testing
      • 3.2.2.2 Lack Of Reimbursement Policies
  • 3.3 Industry Analysis Tools
    • 3.3.1 Porter's Analysis
    • 3.3.2 Pestel Analysis

Chapter 4 Molecular Cytogenetics Market: Application Business Analysis

  • 4.1 Molecular Cytogenetics Market: Application Movement Analysis
  • 4.2 Genetic Disorders
    • 4.2.1 Genetic Disorders Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 4.3 Oncology
    • 4.3.1 Oncology Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 4.4 Personalized Medicine
    • 4.4.1 Personalized Medicine Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 4.5 Other Application
    • 4.5.1 Other Application Market Estimates And Forecast, 2021 - 2033 (USD Million)

Chapter 5 Molecular Cytogenetics Market: Technology Business Analysis

  • 5.1 Molecular Cytogenetics Market: Technology Movement Analysis
  • 5.2 Comparative Genomic Hybridisation
    • 5.2.1 Comparative Genomic Hybridisation Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 5.2.2 Acgh
      • 5.2.2.1 Acgh Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 5.2.3 Scgh
      • 5.2.3.1 Scgh Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 5.3 Fish
    • 5.3.1 Fish Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 5.4 Immunohistochemistry
    • 5.4.1 Immunohistochemistry Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 5.5 Karyotyping
    • 5.5.1 Karyotyping Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 5.5.2 Spectral
      • 5.5.2.1 Spectral Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 5.5.3 Virtual
      • 5.5.3.1 Virtual Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 5.6 Others
    • 5.6.1 Others Market Estimates And Forecast, 2021 - 2033 (USD Million)

Chapter 6 Molecular Cytogenetics Market: Product Business Analysis

  • 6.1 Molecular Cytogenetics Market: Product Movement Analysis
  • 6.2 Instruments
    • 6.2.1 Instruments Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 6.3 Consumables
    • 6.3.1 Consumables Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 6.4 Software & Services
    • 6.4.1 Software & Services Market Estimates And Forecast, 2021 - 2033 (USD Million)

Chapter 7 Molecular Cytogenetics Market: End Use Business Analysis

  • 7.1 Molecular Cytogenetics Market: End Use Movement Analysis
  • 7.2 Clinical & Research Laboratories
    • 7.2.1 Clinical & Research Laboratories Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 7.3 Hospitals & Path Labs
    • 7.3.1 Hospitals & Path Labs Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 7.4 Academic Research Institutes
    • 7.4.1 Academic Research Institutes Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 7.5 Pharmaceutical & Biotech Companies
    • 7.5.1 Pharmaceutical & Biotech Companies Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 7.6 Others
    • 7.6.1 Others Market Estimates And Forecast, 2021 - 2033 (USD Million)

Chapter 7 Molecular Cytogenetics Market: Regional Business Analysis

  • 7.1 Regional Market Snapshot
  • 7.2 North America
    • 7.2.1 North America Molecular Cytogenetics Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.2.2.2 Key Country Dynamics
      • 7.2.2.3 Regulatory Framework
      • 7.2.2.4 Reimbursement Scenario
    • 7.2.3 Canada
      • 7.2.3.1 Canada Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.2.3.2 Key Country Dynamics
      • 7.2.3.3 Regulatory Framework
      • 7.2.3.4 Reimbursement Scenario
  • 7.3 Europe
    • 7.3.1 Europe Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.3.2 UK
      • 7.3.2.1 UK Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.3.2.2 Key Country Dynamics
      • 7.3.2.3 Regulatory Framework
      • 7.3.2.4 Reimbursement Scenario
    • 7.3.3 Germany
      • 7.3.3.1 Germany Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.3.3.2 Key Country Dynamics
      • 7.3.3.3 Regulatory Framework
      • 7.3.3.4 Reimbursement Scenario
    • 7.3.4 Spain
      • 7.3.4.1 Spain Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.3.4.2 Key Country Dynamics
      • 7.3.4.3 Regulatory Framework
      • 7.3.4.4 Reimbursement Scenario
    • 7.3.5 France
      • 7.3.5.1 France Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.3.5.2 Key Country Dynamics
      • 7.3.5.3 Regulatory Framework
      • 7.3.5.4 Reimbursement Scenario
    • 7.3.6 Italy
      • 7.3.6.1 Italy Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.3.6.2 Key Country Dynamics
      • 7.3.6.3 Regulatory Framework
      • 7.3.6.4 Reimbursement Scenario
    • 7.3.7 Denmark
      • 7.3.7.1 Denmark Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.3.7.2 Key Country Dynamics
      • 7.3.7.3 Regulatory Framework
      • 7.3.7.4 Reimbursement Scenario
    • 7.3.8 Sweden
      • 7.3.8.1 Sweden Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.3.8.2 Key Country Dynamics
      • 7.3.8.3 Regulatory Framework
      • 7.3.8.4 Reimbursement Scenario
    • 7.3.9 Norway
      • 7.3.9.1 Norway Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.3.9.2 Key Country Dynamics
      • 7.3.9.3 Regulatory Framework
      • 7.3.9.4 Reimbursement Scenario
  • 7.4 Asia Pacific
    • 7.4.1 Asia-Pacific Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.4.2 Japan
      • 7.4.2.1 Japan Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.4.2.2 Key Country Dynamics
      • 7.4.2.3 Regulatory Framework
      • 7.4.2.4 Reimbursement Scenario
    • 7.4.3 China
      • 7.4.3.1 China Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.4.3.2 Key Country Dynamics
      • 7.4.3.3 Regulatory Framework
      • 7.4.3.4 Reimbursement Scenario
    • 7.4.4 India
      • 7.4.4.1 India Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.4.4.2 Key Country Dynamics
      • 7.4.4.3 Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
    • 7.4.5 South Korea
      • 7.4.5.1 South Korea Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.4.5.2 Key Country Dynamics
      • 7.4.5.3 Regulatory Framework
      • 7.4.5.4 Reimbursement Scenario
    • 7.4.6 Thailand
      • 7.4.6.1 Thailand Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.4.6.2 Key Country Dynamics
      • 7.4.6.3 Regulatory Framework
      • 7.4.6.4 Reimbursement Scenario
    • 7.4.7 Australia
      • 7.4.7.1 Australia Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.4.7.2 Key Country Dynamics
      • 7.4.7.3 Regulatory Framework
      • 7.4.7.4 Reimbursement Scenario
  • 7.5 Latin America
    • 7.5.1 Latin America Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.5.2.2 Key Country Dynamics
      • 7.5.2.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
    • 7.5.3 Mexico
      • 7.5.3.1 Mexico Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.5.3.2 Key Country Dynamics
      • 7.5.3.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
    • 7.5.4 Argentina
      • 7.5.4.1 Argentina Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.5.4.2 Key Country Dynamics
      • 7.5.4.3 Regulatory Framework
      • 7.5.4.4 Reimbursement Scenario
  • 7.6 MEA
    • 7.6.1 MEA Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.6.2.2 Key Country Dynamics
      • 7.6.2.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Saudi Arabia Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.6.3.2 Key Country Dynamics
      • 7.6.3.3 Regulatory Framework
      • 7.6.3.4 Reimbursement Scenario
    • 7.6.4 UAE
      • 7.6.4.1 UAE Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.6.4.2 Key Country Dynamics
      • 7.6.4.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.5 Kuwait
      • 7.6.5.1 Kuwait Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
      • 7.6.5.2 Key Country Dynamics
      • 7.6.5.3 Regulatory Framework
      • 7.6.5.4 Reimbursement Scenario

Chapter 8 Molecular Cytogenetics Market: Competitive Landscape

  • 8.1 Company Categorization
  • 8.2 Strategy Mapping
    • 8.2.1 New Product Launch
    • 8.2.2 Partnerships
    • 8.2.3 Acquisition
    • 8.2.4 Collaboration
    • 8.2.5 Funding
  • 8.3 Company Market Share Analysis, 2024
  • 8.4 Company Profiles
    • 8.4.1 Bioview
      • 8.4.1.1 Company Overview
      • 8.4.1.2 Financial Performance
      • 8.4.1.3 Product Benchmarking
      • 8.4.1.4 Strategic Initiatives
    • 8.4.2 Danaher
      • 8.4.2.1 Company Overview
        • 8.4.2.1.1 Leica Biosystems Nussloch Gmbh
      • 8.4.2.2 Financial Performance
      • 8.4.2.3 Product Benchmarking
      • 8.4.2.4 Strategic Initiatives
    • 8.4.3 Metasystems
      • 8.4.3.1 Company Overview
      • 8.4.3.2 Financial Performance
      • 8.4.3.3 Product Benchmarking
      • 8.4.3.4 Strategic Initiatives
    • 8.4.4 Agilent Technologies, Inc.
      • 8.4.4.1 Company Overview
      • 8.4.4.2 Financial Performance
      • 8.4.4.3 Product Benchmarking
      • 8.4.4.4 Strategic Initiatives
    • 8.4.5 Abbott
      • 8.4.5.1 Company Overview
      • 8.4.5.2 Financial Performance
      • 8.4.5.3 Product Benchmarking
      • 8.4.5.4 Strategic Initiatives
    • 8.4.6 Bio-Rad Laboratories, Inc.
      • 8.4.6.1 Company Overview
      • 8.4.6.2 Financial Performance
      • 8.4.6.3 Product Benchmarking
      • 8.4.6.4 Strategic Initiatives
    • 8.4.7 Illumina, Inc.
      • 8.4.7.1 Company Overview
      • 8.4.7.2 Financial Performance
      • 8.4.7.3 Product Benchmarking
      • 8.4.7.4 Strategic Initiatives
    • 8.4.8 Oxford Gene Technology Ip Limited
      • 8.4.8.1 Company Overview
      • 8.4.8.2 Financial Performance
      • 8.4.8.3 Product Benchmarking
      • 8.4.8.4 Strategic Initiatives
    • 8.4.9 F. Hoffmann-La Roche Ltd
      • 8.4.9.1 Company Overview
        • 8.4.9.1.1 Genentech, Inc.
      • 8.4.9.2 Financial Performance
      • 8.4.9.4 Product Benchmarking
      • 8.4.9.5 Strategic Initiatives
    • 8.4.10 Perkinelmer Inc.
      • 8.4.10.1 Company Overview
      • 8.4.10.2 Financial Performance
      • 8.4.10.3 Product Benchmarking
      • 8.4.10.4 Strategic Initiatives
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦